Vyepti Treatment Linked to Long-Term, Sustained Migraine Relief

Post hoc analysis of the DELIVER clinical trial (NCT04418765) demonstrated long-term improvements in migraine frequency, severity, and headache-related impact, and sustained migraine reductions in individuals with chronic migraine (CM) or episodic migraine (EM) who achieved a ≥50% reduction in monthly migraine days (MMDs) following the first dose of Vyepti (eptinezumab; Lundbeck, Copenhagen, Denmark). These results were presented at the 67th Annual Scientific Meeting of the American Headache Society (AHS).

The 24-week multicenter, parallel-group, randomized, double-blind, placebo-controlled phase 3b clinical trial included 891 eligible participants who were assigned 1:1:1 to receive infusions of placebo, Vyepti 100 mg, or Vyepti 300 mg, followed by a 48-week dose-blinded extension. Post hoc analyses assessed long-term clinical improvements in those achieving ≥50% migraine response in weeks 1 through 12 and evaluated whether ≥50% or ≥75% migraine responder rates achieved by early responders (ie, during weeks 1 through 12 or weeks 1 through 24) with Vyepti treatment were maintained through the 72-week treatment period.

• 43% of participants who received Vyepti 100 mg and 50% of participants who received Vyepti 300 mg achieved ≥50% migraine response at weeks 1 through 12.
• Early responders showed sustained reductions in MMDs, severe migraine attacks, and the 6-item Headache Impact Test (HIT-6) scores through 72 weeks.

• Among early responders, 63% (100 mg group) and 75% (300 mg group) of individuals who achieved a ≥50% reduction in MMDs at weeks 1 through 12, and 71% (100 mg group) and 83% (300 mg group) of individuals who achieved a ≥50% reduction in MMDs at weeks 1 through 24 maintained this response through the 72-week study.
• Among early responders, 37%% (100 mg group) and 65% (300 mg group) of individuals who achieved a ≥75% reduction in MMDs at weeks 1 through 12, and 59% (100 mg group) and 71% (300 mg group) of individuals who achieved a ≥75% reduction in MMDs maintained this response through the 72-week study

Study authors noted that an adequate trial of ≥6 months assessing Vyepti treatment should be considered to ensure optimal clinical benefit can be realized. This study was supported by H. Lundbeck A/S.